Human papillomavirus genotypes among women with or without HIV infection: an epidemiological study of Moroccan women from the Souss area

Infectious Agents and Cancer

Christiane Mougin³  Said Chouham¹  Jean-Luc Prétet³  Mariette Mercier²  Mohamed Aksim⁴  Bouchra Mouaouya⁴  Hicham Elannaz⁵  Essaada Belglaiaa² 

[1] Laboratoire de Biologie Cellulaire et Génétique Moléculaire, Faculté des Sciences, Université Ibn Zohr, Agadir 80000, Maroc;EA 3181, Lab Ex LipSTIC ANR-11-LABX-0021, Université de Franche-Comté UBFC, Besançon, F-25000, France;Laboratoire de Biologie Cellulaire et Moléculaire, Inserm CIC 1431, CHRU Jean Minjoz, Boulevard Fleming, Besançon, 25000, France;Service d’anatomopathologie, Hôpital Hassan II, Agadir, Maroc;Laboratoire de biologie moléculaire, 5ème Hôpital Militaire, Guelmim, Maroc

关键词: Morocco;    Cervical cancer;    Pap smear;    HIV;    HPV;   

Others  :  1234886
DOI  :  10.1186/s13027-015-0040-y

 received in 2015-07-13, accepted in 2015-10-21,  发布年份 2015

【 摘 要 】

Background

Data on Human PapillomaVirus (HPV) infection are scarce in Morocco. The objective of the study was to determine the prevalence of HPV and cervical cytology abnormalities in women from the Souss area, Morocco.

Methods

Two hundred and thirty two women who attended the Hassan II hospital (Agadir, Morocco) were recruited in this study. Socio-economic data, sexual activity, reproductive life, history of Pap smear, smoking and HIV status were recorded. Cervical samples were taken using an Ayre spatula. Cytology was reported using the Bethesda system. HPVs were first detected by MY09/11 consensus PCR and then genotyped with INNO-LiPA ^®assay. Data were analyzed using the logistic regression model.

Results

The median age of women was 42 years (18–76 years). HIV prevalence was 36.2 %. Any HPV type prevalence was 23.7 % in the study population, lower in HIV-negative women (13.3 %) than in HIV-positive women (39.3 %). HPV16 was the most prevalent type (6.5 %), followed by HPV53 and HPV74 (3.4 % each). Most women had normal cervical smears (82 %), the remaining were diagnosed with LGSIL (13 %) and HGSIL (5 %). HPV was detected in 17.4 % of normal smears, 43.4 % of LGSIL and 75 % of HGSIL. HIV status was the most powerful predictor of high risk (hr) and probable hr (phr) HPV infection (odds ratio 4.16, 95 % confidence interval 1.87–9.24, p = 0.0005) followed by abnormal cytology (OR 3.98, 95 % CI 1.39–11.40, p = 0.01), independently of socio-demographic and behavioral risk factors.

Conclusions

In a Moroccan hospital based-population of the Souss area, HPV infections are frequently detected. In addition, high prevalence of hr and phrHPVs and precancerous lesions among HIV-positive women is likely associated with an increased risk of cervical cancer. This highlights the need for HPV and cervical cancer prevention campaigns in Morocco.

【 授权许可】

   
2015 Belglaiaa et al.

【 图 表 】

Fig. 1.

【 参考文献 】

• [1]Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al.: Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995, 87(11):796-802.
• [2]Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al.: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348(6):518-27.
• [3]Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al.: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189(1):12-9.
• [4]ICO Information Centre on HPV and Cancer. Human Papillomavirus and related cancers. Institut Català d’Oncologia. Fact Sheet 2014 (Dec 15). http://www.hpvcentre.net/statistics/reports/MAR_FS.pdf 2014.
• [5]Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al.: A review of human carcinogens--Part B: biological agents. Lancet Oncol 2009, 10(4):321-2.
• [6]Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, et al.: Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004, 111(2):278-85.
• [7]Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL: Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006, 24(Suppl 3):S3/26-34.
• [8]de Villiers EM, Wagner D, Schneider A, Wesch H, Miklaw H, Wahrendorf J, et al.: Human papillomavirus infections in women with and without abnormal cervical cytology. Lancet 1987, 2(8561):703-6.
• [9]McClelland RS, Ndinya-Achola JO, Baeten JM: Re: distinguishing the temporal association between women’s intravaginal practices and risk of human immunodeficiency virus infection: a prospective study of South African women. Am J Epidemiol 2007, 165(4):474-5.
• [10]Ferenczy A, Coutlee F, Franco E, Hankins C: Human papillomavirus and HIV coinfection and the risk of neoplasias of the lower genital tract: a review of recent developments. CMAJ 2003, 169(5):431-4.
• [11]Clifford GM, Goncalves MA, Franceschi S: Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS 2006, 20(18):2337-44.
• [12]Strickler HD, Burk RD, Fazzari M, Anastos K, Minkoff H, Massad LS, et al.: Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 2005, 97(8):577-86.
• [13]Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA: Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 2009, 101(16):1120-30.
• [14]De Vuyst H, Lillo F, Broutet N, Smith JS: HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. Eur J Cancer Prev 2008, 17(6):545-54.
• [15]Rapport national 2014. Mise en œuvre de la déclaration politique sur le VIH/sida. Royaume du Maroc, Ministère de la Santé. www.unaids.org/sites/default/files/country/documents//MAR_narrative_report_2014.pdf. 2014.
• [16]Manos MM, Ting Y, Wright DK, Lewis AJ, Broker TR, Wolinsky SM: The use of polymerase chain reaction amplification for the detection of genital human. Cancer Cells 1989, 7:209-14.
• [17]de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al.: Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012, 13(6):607-15.
• [18]Alhamany Z, El Mzibri M, Kharbach A, Malihy A, Abouqal R, Jaddi H, et al.: Prevalence of human papillomavirus genotype among Moroccan women during a local screening program. J Infect Dev Ctries 2010, 4(11):732-9.
• [19]Chaouki N, Bosch FX, Munoz N, Meijer CJ, El Gueddari B, El Ghazi A, et al.: The viral origin of cervical cancer in Rabat, Morocco. Int J Cancer 1998, 75(4):546-54.
• [20]EL Gnaoui N, Benchakroun N, Benider A, Hassar M, Saile R, Benoma H: Typing of human papillomavirus and evaluation of risk factors associated with cervical cancer in Morocco. Eur J Sci Res 2009, 31:229-36.
• [21]Amrani M, Lalaoui K, El Mzibri M, Lazo P, Belabbas MA: Molecular detection of human papillomavirus in 594 uterine cervix samples from Moroccan women (147 biopsies and 447 swabs). J Clin Virol 2003, 27(3):286-95.
• [22]Birrou K, Tagajdid R, Elannaz H, Elkochri S, Abi R, Zouhdi M, et al.: Human papillomavirus genotype prevalence and distribution among Moroccan pregnant women. Int J Res Med Sci 2015, 3:95-9.
• [23]Bennani B, Bennis S, Nejjari C, Ouafik L, Melhouf MA, El Rhazi K, et al.: Correlates of HPV: a cross-sectional study in women with normal cytology in north-central Morocco. J Infect Dev Ctries 2012, 6(7):543-50.
• [24]Berumen J, Ordonez RM, Lazcano E, Salmeron J, Galvan SC, Estrada RA, et al.: Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control study. J Natl Cancer Inst 2001, 93(17):1325-30.
• [25]Jacobs MV, Walboomers JM, Snijders PJ, Voorhorst FJ, Verheijen RH, Fransen-Daalmeijer N, et al.: Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer 2000, 87(2):221-7.
• [26]Rolon PA, Smith JS, Munoz N, Klug SJ, Herrero R, Bosch X, et al.: Human papillomavirus infection and invasive cervical cancer in Paraguay. Int J Cancer 2000, 85(4):486-91.
• [27]Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, et al.: Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008, 26(Suppl 10):K1-16.
• [28]Usubutun A, Alemany L, Kucukali T, Ayhan A, Yuce K, de Sanjose S, et al.: Human papillomavirus types in invasive cervical cancer specimens from Turkey. Int J Gynecol Pathol 2009, 28(6):541-8.
• [29]Herrero R, Castle PE, Schiffman M, Bratti MC, Hildesheim A, Morales J, et al.: Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste. Costa Rica J Infect Dis 2005, 191(11):1796-807.
• [30]Pretet JL, Jacquard AC, Carcopino X, Charlot JF, Bouhour D, Kantelip B, et al.: Human papillomavirus (HPV) genotype distribution in invasive cervical cancers in France: EDITH study. Int J Cancer 2008, 122(2):428-32.
• [31]Pretet JL, Jacquard AC, Carcopino X, Monnier-Benoit S, Averous G, Soubeyrand B, et al.: Human papillomavirus genotype distribution in high grade cervical lesions (CIN 2/3) in France: EDITH study. Int J Cancer 2008, 122(2):424-7.
• [32]Meftah el khair M, Ait Mhand R, Mzibri ME, Ennaji MM: Risk factors of invasive cervical cancer in Morocco. Cell Mol Biol (Noisy-le-Grand) 2009, 55:OL1175-85.
• [33]Carrillo-Garcia A, Ponce-de-Leon-Rosales S, Cantu-de-Leon D, Fragoso-Ontiveros V, Martinez-Ramirez I, Orozco-Colin A, et al.: Impact of human papillomavirus coinfections on the risk of high-grade squamous intraepithelial lesion and cervical cancer. Gynecol Oncol 2014, 134(3):534-9.
• [34]Chaturvedi AK, Katki HA, Hildesheim A, Rodriguez AC, Quint W, Schiffman M, et al.: Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease. J Infect Dis 2011, 203(7):910-20.
• [35]Yang Z, Cuzick J, Hunt WC, Wheeler CM: Concurrence of multiple human papillomavirus infections in a large US population-based cohort. Am J Epidemiol 2014, 180(11):1066-75.
• [36]van der Graaf Y, Molijn A, Doornewaard H, Quint W, van Doorn LJ, van den Tweel J: Human papillomavirus and the long-term risk of cervical neoplasia. Am J Epidemiol 2002, 156(2):158-64.
• [37]Stuardo V, Agusti C, Godinez JM, Montoliu A, Torne A, Tarrats A, et al.: Human papillomavirus infection in HIV-1 infected women in Catalonia (Spain): implications for prevention of cervical cancer. PLoS One 2012, 7(10):e47755.
• [38]Louie KS, de Sanjose S, Mayaud P: Epidemiology and prevention of human papillomavirus and cervical cancer in sub-Saharan Africa: a comprehensive review. Trop Med Int Health 2009, 14(10):1287-302.
• [39]Temmerman M, Tyndall MW, Kidula N, Claeys P, Muchiri L, Quint W: Risk factors for human papillomavirus and cervical precancerous lesions, and the role of concurrent HIV-1 infection. Int J Gynaecol Obstet 1999, 65(2):171-81.
• [40]Palefsky JM, Minkoff H, Kalish LA, Levine A, Sacks HS, Garcia P, et al.: Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst 1999, 91(3):226-36.
• [41]Del Mistro A, Chieco BL: HPV-related neoplasias in HIV-infected individuals. Eur J Cancer 2001, 37(10):1227-35.
• [42]Riethmuller D, Jacquard AC, Lacau St Guily J, Aubin F, Carcopino X, Pradat P, et al.: Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France. BMC Public Health 2015, 15:453. BioMed Central Full Text